Immunotherapy plus standard treatment shows promise for head and neck cancer
Disease control
Completed
This early-phase study tested adding the immunotherapy drug pembrolizumab to standard chemoradiation for people with advanced head and neck cancer. 59 participants received the combination to see if it was safe and helped shrink tumors. The goal was to improve cancer control with…
Phase: PHASE1 • Sponsor: Sanford Health • Aim: Disease control
Last updated May 01, 2026 15:57 UTC